


- EURneffy® is a nasal spray delivering 1 dose of adrenaline.
- EURneffy® is indicated in the emergency treatment of severe allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children aged 4 years and over weighing 15 kg or more.
- Education of patients and caregivers is crucial to ensure timely and correct handling and administration of adrenaline in emergency situations, and consequently an important part of risk management for the patient. Knowledge of proper administration technique and device care furthermore decreases the risk of accidental or unnecessary drug administration, minimizing the risk of adverse reactions.
- The purpose of this checklist is to aid you as the prescriber in instructing the patient and/or caregivers in correct use, storage and care of EURneffy®.

Educational materials regarding the correct use, handling and storage of EURneffy® are available to patients and caregivers:

- EURneffy® Trainer
- Instructional Video
- Patient Brochure
- Instructions for use provided with the product in the blister pack

EURneffy nasal spray



- Please ensure that you as a prescriber are able to answer 'yes' to the questions below related to prescription, user instruction, handling and storage of EURneffy®.

Prescription

Is the patient 4 years or older and weigh between 15 kg and 30 kg?	<i>Prescribe EURneffy® 1 mg</i>
Is the patient 4 years or older and weigh 30 kg or more?	<i>Prescribe EURneffy® 2 mg</i>
Has the patient been prescribed 2 EURneffy® nasal sprays?	
Has the patient been recommended to carry 2 EURneffy® nasal sprays with them at all times?	

Instructions for use

Has the patient/caregiver been instructed under which circumstances EURneffy® should be used?	
Has the patient/caregiver been shown the correct handling and administration technique?	
Has the patient/caregiver been instructed to contact emergency services (dial 999) to request an ambulance and to state "anaphylaxis" after using their EURneffy® even if the symptoms seem to improve?	
Is the patient/caregiver aware to administer a second EURneffy® after 5 minutes in the absence of clinical improvement or in case of any error in administration?	
Has the patient/cargiver been provided with a EURneffy® Trainer for future administration technique training?	
Has the patient/caregiver been instructed not to carry or store their EURneffy® Trainer with their EURneffy® nasal spray?	
Has the patient/caregiver been recommended to review the educational materials for additional training and guidance available at www.eurneffy.eu ?	

Storage and care

Has the patient/caregiver been instructed that EURneffy® does not require any special storage conditions?	
Has the patient/caregiver been informed that the nasal spray will not function if accidentally frozen? If frozen, the nasal spray should be allowed to thaw for at least 1 hour; do not use if the content is still frozen or not completely thawed.	
Has the patient/caregiver been advised to regularly check their EURneffy® and ensure it is replaced within the expiry date?	

EURneffy® instructions for use




1. Hold

Hold the nasal spray as shown. Hold the nasal spray with your thumb on the bottom of the plunger and one finger on either side of the nozzle.

DO NOT pull or push on the plunger.

DO NOT test or pre-spray; each nasal spray has only one dose.



2. Place

Insert the tip of nasal spray into a nostril until your fingers touch your nose. Keep the nozzle straight into the nose pointed toward the forehead.

DO NOT angle the nasal spray to the inner or outer walls of the nose.



3. Press

Press the plunger up firmly until it snaps up and sprays into the nostril.

After using EURneffy®

Seek emergency medical assistance immediately (dial 999) as you might need further treatment for your anaphylaxis.

When using EURneffy®

If you're a parent or caregiver using EURneffy®, ensure the device is held correctly for proper administration. Patients should lie down with feet raised. If this makes you breathless, you can gently sit up. You should not change position suddenly and should lie down again as soon as possible. You should not stand up even if someone encourages you to. You should stay lying down even if you feel better. Pregnant women should lie on their left side. Unconscious patients should be placed on their side in the recovery position to prevent choking.

Monitor patient symptoms

If symptoms continue to worsen or reoccur after 5 minutes, or in case of any error in administration, use a new EURneffy® nasal spray, to give a second dose in the SAME nostril as the first dose and seek emergency medical assistance as you might need further treatment for your anaphylaxis.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.